Market Overview

Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH

Incyte Corporation (Nasdaq: INCY) announced today that more than 35
analyses from clinical studies of Jakafi® (ruxolitinib) were
presented at the 2013 American Society of Hematology (ASH) Annual
Meeting from Dec. 7 to 10 in New Orleans. Jakafi, an oral JAK1/JAK2
inhibitor, is FDA-approved for the treatment of patients with
intermediate or high-risk myelofibrosis (MF).

“Myelofibrosis is a debilitating, life-threatening blood cancer with
limited treatment options. It is, therefore, rewarding to see that the
expanding body of clinical data for Jakafi shows durable reductions in
spleen volume and clinically meaningful improvements in health-related
quality of life measures and supports a survival benefit for patients,”
stated Paul A. Friedman, M.D., Incyte's Chief Executive Officer and

See full press release

Posted-In: News Guidance Buybacks Management Global

 

Related Articles (INCY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters